Onkológia 1/2014
Sorafenib and hepatocellular carcinoma
Multikinase inhibitor sorafenib is considered the standard systematic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A) and advanced-stage HCC. The most freguent sorafenib associated advanced events are skin toxicity, hand foot syndrom, fatigue and diarrhea. The cirrhosis and its complications can negatively affect the tolerability and the efficacy of sorafenib. This review provides the most relevant clinical data about the efficacy and the safety of sorafenib in patients with hepatocellular carcinoma.
Keywords: sorafenib, hepatocellular carcinoma, advanced events, cirrhosis, clinical data.
